These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 32559285)

  • 1. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
    Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
    J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Repurposing Study Pinpoints Potential COVID-19 Antivirals.
    Abbasi J
    JAMA; 2020 Sep; 324(10):928. PubMed ID: 32897326
    [No Abstract]   [Full Text] [Related]  

  • 4. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
    Severa M; Farina C; Salvetti M; Coccia EM
    Front Immunol; 2020; 11():1459. PubMed ID: 32655578
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
    Softic L; Brillet R; Berry F; Ahnou N; Nevers Q; Morin-Dewaele M; Hamadat S; Bruscella P; Fourati S; Pawlotsky JM; Ahmed-Belkacem A
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32376613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2.
    Meister TL; Brüggemann Y; Todt D; Conzelmann C; Müller JA; Groß R; Münch J; Krawczyk A; Steinmann J; Steinmann J; Pfaender S; Steinmann E
    J Infect Dis; 2020 Sep; 222(8):1289-1292. PubMed ID: 32726430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
    Caly L; Druce JD; Catton MG; Jans DA; Wagstaff KM
    Antiviral Res; 2020 Jun; 178():104787. PubMed ID: 32251768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral activities of type I interferons to SARS-CoV-2 infection.
    Mantlo E; Bukreyeva N; Maruyama J; Paessler S; Huang C
    Antiviral Res; 2020 Jul; 179():104811. PubMed ID: 32360182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing old drugs as antiviral agents for coronaviruses.
    Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
    Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Human Respiratory Epithelium.
    Milewska A; Kula-Pacurar A; Wadas J; Suder A; Szczepanski A; Dabrowska A; Owczarek K; Marcello A; Ochman M; Stacel T; Rajfur Z; Sanak M; Labaj P; Branicki W; Pyrc K
    J Virol; 2020 Jul; 94(15):. PubMed ID: 32434888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 RNA polymerase as target for antiviral therapy.
    Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM
    J Transl Med; 2020 May; 18(1):185. PubMed ID: 32370758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).
    Yuan S; Chan CC; Chik KK; Tsang JO; Liang R; Cao J; Tang K; Cai JP; Ye ZW; Yin F; To KK; Chu H; Jin DY; Hung IF; Yuen KY; Chan JF
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32532085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
    Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
    Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.
    Salgado-Benvindo C; Thaler M; Tas A; Ogando NS; Bredenbeek PJ; Ninaber DK; Wang Y; Hiemstra PS; Snijder EJ; van Hemert MJ
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
    Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D
    Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of SARS-CoV-2 by type I and type III interferons.
    Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F
    J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
    Choy KT; Wong AY; Kaewpreedee P; Sia SF; Chen D; Hui KPY; Chu DKW; Chan MCW; Cheung PP; Huang X; Peiris M; Yen HL
    Antiviral Res; 2020 Jun; 178():104786. PubMed ID: 32251767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib is not a potent anti-SARS-CoV-2 drug.
    Zhao H; Mendenhall M; Deininger MW
    Leukemia; 2020 Nov; 34(11):3085-3087. PubMed ID: 32999432
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.